Abstract
To the Editor:
Lenz et al. (Nov. 27 issue)
1
report the results of an important study of gene expression and survival in patients with diffuse large-B-cell lymphoma. We reassessed the performance of a survival predictor that we had previously reported
2
by applying it to the expression profiles of tumors from patients described by Lenz et al. Our model performed well in predicting overall survival in these patients, whether they were treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or with CHOP in combination with rituximab (R-CHOP) (P<0.001) (Figure 1). Furthermore, when risk was in the model as a continuous variable, . . .
